[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-disorder":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100507832","phase-2-post-thrombectomy-intra-arterial-tenecteplase-for-acute-management-of-non-retrievable-thrombus-and-no-reflow-in-emergent-stroke-100507832",false,"NCT05892510","Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke","Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke (EXTEND-AGNES TNK)","Inclusion Criteria:\n\n* Adult participants (age≥18 years) presenting with ischemic stroke with arterial LVO on CT\u002FMR Angiogram of the intracranial internal carotid or middle cerebral artery (MCA) first segment (M1) or proximal second segment (M2) committed to thrombectomy using standard criteria within 24 hours of onset:\n* For 0-6 hours of symptom onset: Presence of arterial occlusion as defined above and ASPECTS≥3 on NCCT\n* For 6-24 hours of symptom onset: Additional imaging criteria on CTP or MRI perfusion of core volume \\\u003C100ml.\n* Qualifying CT\u002FMR within 4hrs of randomisation (repeat CT for transferred participants required if \\>4hr)\n* Pre-stroke Modified Rankin Scale (mRS) score of ≤2 (mild pre-existing disability permitted)\n* Local legal requirements for consent have been satisfied.\n\nExclusion Criteria:\n\n* Intracranial hemorrhage identified by CT or MRI\n* ASPECTS 0-2 on NCCT\n* CTP or MRI perfusion ischemic core volume \\>100ml if presenting within 6-24 hours from symptoms onset\n* Anticipated endovascular stenting required for intracranial or extracranial atherosclerotic stenosis\u002Focclusion.\n* More than six retrieval attempts in the same vessel\n* Alteplase being infused within 30 minutes (\\~5x half-life) of anticipated trial drug administration\n* Contraindication to imaging with contrast agents\n* Any condition (eg.mid-arterial phase early venous filling) that in the judgment of investigators could impose hazards if study therapy is initiated\n* Pregnant women.\n* Current participation in another intervention research study that includes experimental interventions beyond standard-of-care.\n* Anticoagulation. INR ≤1.7 if on warfarin, and dabigatran reversal by idarucizumab are permitted.\n* Other standard contraindications to thrombolysis apart from time window.\n* Known terminal illness such that the participants would not be expected to survive a year.\n* Planned withdrawal of care or comfort care measures.","ALL","18 Years",{"count":19,"type":20},462,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","Multicentre, prospective, Multi-arm Multi-stage (MAMS) seamless phase 2b\u002F3 interventional randomized placebo-controlled double-blinded parallel-assignment (2 arms with 1:1 randomization) efficacy and safety trial to test intra-arterial tenecteplase at the completion of thrombectomy versus best practice in participants with anterior circulation LVO receiving mechanical thrombectomy within 24 hours of symptoms onset.",[27,28,29,30],"Ischemic Stroke, Acute","Cerebrovascular Disorders","Brain Disorder","Central Nervous System Diseases",[32,33,34,35],"Tenecteplase","Fibrinolytic agents","Thrombectomy","No-reflow","RECRUITING","2026-05-14",{"date":39,"type":40},"2026-05-18","ACTUAL",{"date":42,"type":40},"2024-06-01",{"date":44,"type":20},"2027-11-30",{"name":46,"class":47},"University of Melbourne","OTHER",12,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100580440","effect-of-untact-upper-extremity-rehabilitation-using-smart-glove-for-late-subacute-and-chronic-patients-with-brain-disorder-100580440","NCT06837324","Effect of Untact Upper Extremity Rehabilitation Using Smart Glove for Late Subacute and Chronic Patients With Brain Disorder","A Multicenter Confirmation Clinical Trial of Untact Upper Extremity Rehabilitation Using Smart Glove for Late Subacute and Chronic Patients With Brain Disorder - a Randomized Single-blinded Controlled Trial","brain disorder","Inclusion Criteria:\n\n* Patients with brain disorder aged 19 to 85 years old\n* patients with hemiparesis lasting for more than 3 months due to neurological diseases (stroke, traumatic brain injury, brain tumor) and impaired upper limb function\n* Patients with spasticity of the wrist and finger flexors and extensors on the affected side, with a Modified Ashworth Scale (MAS) score of 1+ or lower\n* Participants with sufficient cognitive function to understand the instructions from the researcher and the smart glove, and to perform the tasks (K-MMSE ≥21)\n\nExclusion Criteria:\n\n* pre-existing significant neurogenic disorders\n* major psychiatric disorders such as schizophrenia, bipolar disorder, or dementia\n* History of diseases that caused pain or muscle atrophy in the affected upper limb before the onset of the neurological disease, which interfered with rehabilitation\n* Severe spasticity of the affected upper limb (Modified Ashworth Scale score ≥3)\n* skin disorders or open wounds on the affected upper limb\n* Amputation, fractures, or soft tissue-related diseases or injuries on the affected upper limb\n* severe pain that interferes with rehabilitation of the affected upper limb (Numeric Rating Scale \\> 6)\n* Inability to maintain a seated posture for more than 10 minutes\n* Significant visual impairment to the extent that the screen cannot be recognized when using the smart glove","19 Years","85 Years",{"count":60,"type":20},40,[62],"NA","The aim is to clinically validate the clinical efficacy, usability, and safety of home-based upper limb rehabilitation training using the Neofect Smart Glove by comparing the effects between a group using the home-based Neofect Smart Glove and a group performing conventional home-based occupational therapy in patients with upper limb dysfunction in the late subacute and chronic stages of neurological diseases.",[29,65],"Home Based Rehabilitation","2026-04-23",{"date":68,"type":40},"2026-04-24",{"date":70,"type":40},"2025-04-11",{"date":72,"type":20},"2026-12-31",{"name":74,"class":47},"Samsung Medical Center",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":91,"locationsCount":75},"100580443","effect-of-untact-upper-extremity-rehabilitation-using-a-smart-board-for-late-subacute-and-chronic-patients-with-brain-disorder-100580443","NCT06837363","Effect of Untact Upper Extremity Rehabilitation Using a Smart Board for Late Subacute and Chronic Patients With Brain Disorder","A Multicenter Confirmation Clinical Trial of Untact Upper Extremity Rehabilitation Using Smart Board for Late Subacute and Chronic Patients With Brain Disorder - a Randomized Single-blinded Controlled Trial","Inclusion Criteria:\n\n* Patients with neurological diseases aged 19 to 85 years old\n* Patients with hemiparesis lasting for more than 3 months due to neurological diseases (stroke, traumatic brain injury, brain tumor) and impaired upper limb function\n* Patients with shoulder flexor and adductor muscle strength of MRC grade 2 or higher\n* Patients with shoulder extensor and abductor spasticity of MAS grade 1+ or lower\n* Participants with sufficient cognitive function to understand the instructions from the researcher and the smart board, and to perform the tasks (K-MMSE ≥21)\n\nExclusion Criteria:\n\n* pre-existing significant neurogenic disorders\n* major psychiatric disorders such as schizophrenia, bipolar disorder, or dementia\n* History of diseases that caused pain or muscle atrophy in the affected upper limb before the onset of the neurological disease, which interfered with rehabilitation\n* Severe spasticity of the affected upper limb (Modified Ashworth Scale score ≥3)\n* skin disorders or open wounds on the affected upper limb\n* Amputation, fractures, or soft tissue-related diseases or injuries on the affected upper limb\n* severe pain that interferes with rehabilitation of the affected upper limb (Numeric Rating Scale \\> 6)\n* Inability to maintain a seated posture for more than 10 minutes, which is required for using the smart board\n* Significant visual impairment to the extent that the screen cannot be recognized when using the smart board",{"count":60,"type":20},[62],"The aim is to clinically validate the clinical efficacy, usability, and safety of home-based upper limb rehabilitation training using the Neofect Smart Board by comparing the effects between a group using the home-based Neofect Smart Board and a group performing conventional home-based occupational therapy in patients with upper limb dysfunction in the late subacute and chronic stages of neurological diseases.",[65,29],{"date":68,"type":40},{"date":89,"type":40},"2025-04-01",{"date":72,"type":20},{"name":74,"class":47}]